Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

NEXT STORY
H1 2021: Tecan reports substantial double-digit growth in sales and more than a doubling in net profit – on top of an already strong performance in the prior-year period
PREV STORY
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Interpace Diagnostics Announces Expansion of LabCorp National Agreement

PARSIPPANY, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” ...

author_avatar
NASDAQ Market News

BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced ...

author_avatar
NASDAQ Market News

Kura Oncology Reports Second Quarter 2016 Financial Results

Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid ...

author_avatar
NASDAQ Market News